Page last updated: 2024-10-15

2'-deoxyguanosine 3'-phosphate

Description

2'-deoxyguanosine 3'-monophosphate : A deoxyguanosine phosphate having a monophosphate group located at the 3'-position. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID135449322
CHEBI ID55553
SCHEMBL ID2985702
MeSH IDM0105116

Synonyms (25)

Synonym
2'-deoxyguanosine 3'-(dihydrogen phosphate)
2'-deoxyguanosine 3'-monophosphate
CHEBI:55553
3PD ,
2-amino-9-(2-deoxy-3-o-phosphonopentofuranosyl)-1,9-dihydro-6h-purin-6-one
2'-deoxyguanosine 3'-phosphate
2'-deoxy-3'-guanylic acid
6220-62-8
m2r74jg5b5 ,
einecs 228-296-9
unii-m2r74jg5b5
2'-deoxyguanosine 3'-monophosphate ammonium salt
SCHEMBL2985702
2'-deoxyguanosine-3'-monophosphate
3'-dgmp
J-000794
Q27124367
DTXSID40977782
9-(2-deoxy-3-o-phosphonopentofuranosyl)-2-imino-3,9-dihydro-2h-purin-6-ol
2-deoxyguanosine 3-(dihydrogen phosphate)
deoxyguanosine 3'-phosphate
3'-guanylic acid, 2'-deoxy-
deoxyguanosine 3'-monophosphate
guanosine, 2'-deoxy-, 3'-(dihydrogen phosphate)
((2r,3s,5r)-5-(2-amino-6-oxo-3h-purin-9-yl)-2-(hydroxymethyl)tetrahydrofuran-3-yl) dihydrogen phosphate

Dosage Studied

ExcerptReference
" Following dosing with N-desmethyltamoxifen, the major product co-eluted with one of the main peaks seen following treatment of rats with tamoxifen."( Further characterization of the DNA adducts formed in rat liver after the administration of tamoxifen, N-desmethyltamoxifen or N, N-didesmethyltamoxifen.
Brown, K; Heydon, RT; Jukes, R; Martin, EA; White, IN, 1999
)
" Using these standard markers, we analyzed the hepatic DNA adducts of female DBA/2 mice treated with tamoxifen at a dosage of 120 mg/kg/day for 7 days by (32)P-post-labeling coupled with an HPLC/radioactive detector."( Identification of hepatic tamoxifen-DNA adducts in mice: alpha-(N(2)-deoxyguanosinyl)tamoxifen and alpha-(N(2)-deoxyguanosinyl)tamoxifen N-oxide.
Kanno, Y; Komaki, K; Lin, CX; Momen, MA; Monden, Y; Ravindernath, A; Shibutani, S; Suwa, M; Suzuki, M; Ueyama, Y; Umemoto, A, 2000
)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
purine 2'-deoxyribonucleoside 3'-monophosphate
deoxyguanosine phosphate
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (15)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (13.33)18.7374
1990's7 (46.67)18.2507
2000's6 (40.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other15 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]